INTRODUCTION INTRODUCTION
• Psoriasis is a chronic disease that affects an estimated 3.2% of adults in the United States and often requires prolonged therapy to achieve long-term symptom improvement. 1, 2 • Published evidence suggests the US cost burden associated with psoriasis includes total direct annual costs, estimated in 2013 to be between $51.7 and $63.2 billion. 3 • Research indicates that due to concerns with long-term safety, administration challenges, loss of response over time, and cost, discontinuation of treatment regimens is common. [4] [5] [6] • Apremilast was approved by the US Food and Drug Administration in 2014 for the treatment of psoriasis and psoriatic arthritis. 7 -Safety and efficacy was established in 2 pivotal studies, ESTEEM 1 (NCT01194219) 8 and ESTEEM 2 (NCT01232283). 9 • Other treatments for moderate to severe psoriasis include but are not limited to injectable biologics such as tumor necrosis factor-alpha blockers (eg, etanercept, adalimumab, and infliximab), interleukins 12 and 23 antagonists (eg, ustekinumab), or interleukin 17A antagonists (eg, secukinumab).
• Cost per responder analyses assess the response rates and incremental costs per responder within the context of a clinical trial but cannot provide an economic evaluation under real-world conditions.
• Time free of therapy discontinuation (persistence) can be assessed using medical claims and provides a surrogate measure of effectiveness as patients who persist on a therapy are presumably receiving a benefit from an effective treatment.
• Currently, there are no comparative published data on the long-term cost per persisting patient among adult patients being treated with apremilast versus biologic therapy in a real-world care setting.
OBJECTIVE OBJECTIVE
• The objective of this study was to compare the cost per persisting patient among psoriasis patients initiating apremilast or a biologic therapy from the US managed care perspective.
METHODS METHODS

Study Design
• This observational, retrospective cohort study was conducted using MarketScan Commercial and Medicare Supplemental Databases (2013-2015) ( Table 1) . 
Inclusion Criteria
• Adult patients with at least 2 diagnosis codes for psoriasis (ICD-9:696.1)*
• At least 1 prescription claim for either apremilast or biologic therapies ( Figure 1) • The index date was selected among the dates of a psoriasis treatment on or after the FDA approval of apremilast (March 21, 2014), following the definition of cohorts below.
-Patients who had at least 1 prescription fill for apremilast were classified in the apremilast cohort, regardless of whether they used any other psoriasis treatment.
-Among psoriasis patients who did not use apremilast, patients who were initiated on a biologic (i.e., adalimumab, etanercept, infliximab, secukinumab, and ustekinumab) during the index period were classified in the biologic cohort.
To ensure new patient starts, biologic users were required to be treatment-naïve to the index medication in the pre-index period, although prior use of a different biologic was not reason for exclusion.
• Patients were required to be continuously enrolled with full access to medical and pharmacy claims for ≥6 months prior to index and ≥3 months post-index. 
Assessment
Outcome: Persistence • Treatment discontinuation was defined as a gap of at least 60 consecutive days after the end of supply of a prescription fill. The date of discontinuation was set as the last day of supply of the index treatment before the gap.
• Persistence was measured from the index date to the first index treatment discontinuation.
• Observation periods were censored if patients did not discontinue the index treatment by the end of the study period.
• This analysis only included discontinuation at 6 months among those patients who had at least 6 months of continuous insurance coverage.
-Patients with at least 6 months of continuous insurance may have discontinued the index drug before the 6 th month following the index date.
Outcome: Healthcare Costs • Healthcare costs (2014 US$) were defined as the sum of pharmacy and medical service costs and included: inpatient costs, outpatient costs (including physician office visits and intravenous infusion procedures), emergency costs, and all other service costs (e.g., laboratory, radiology, and other ancillary services).
• Psoriasis-related healthcare costs were identified using medical claims with a diagnosis for psoriasis (ICD-9-696.1).
Outcome: Cost per Persisting Patient
• This study used persistence as a surrogate endpoint for effectiveness, as compared to a cost per responder analysis, which uses efficacy from clinical trials.
-Patients who persist at month 6 were assumed to be receiving a benefit from therapy and therefore therapy was effective.
• The cost per persisting patient was calculated by dividing cumulative cost at month 6 by persistence rate at month 6 for apremilast and biologic therapy.
Statistical Analysis
• Persistence was estimated using Kaplan Meier (KM) survival analyses. Persistence rates were reported at 6 months following the index date.
• Summary statistics were used to express results in cost per patient per month and were reported separately for disease-specific psoriasis costs.
• P values were estimated using non-parametric bootstrap resampling techniques of 499 iterations.
RESULTS RESULTS
Patients
• In total, 839 patients initiating apremilast and 1,981 patients initiating biologic therapies met the inclusion criteria ( Figure 2 ).
• Mean enrollment time post-index was 5.4 months for apremilast and 8.3 months for biologic therapies. Patients continuously enrolled in their healthcare plan for ≥6 months before and ≥3 months after psoriasis treatment initiation n=32,001 (52.9%)
• The baseline demographics of both treatment groups are reported in Table 2 . 
Persistence
• At 6 months post-index, persistence to initiated drug was similar between the apremilast and biologic cohorts (apremilast: 67.1%, 95% CI: 63.6-70.5 vs. biologics: 68.5%, 95% CI: 66.3-70.6) ( Figure 3) . • The cost per persisting patient was $10,463 lower for apremilast compared with biologics ($18,652 vs. $29,115, respectively; Figure 5 ). • The cost to achieve 100 persisting patients at month 6 was $1,865,200 for apremilast and $2,911,500 for biologics.
CONCLUSIONS CONCLUSIONS
• Mean cumulative cost per patient was lower for apremilast than for biologics. When taking into account the cost of persisting patients, over 6 months of therapy the difference increases to more than $10,000.
• Apremilast therapy is associated with a persistence rate similar to that with biologic therapy but at significantly reduced costs.
LIMITATIONS LIMITATIONS
• Although the database is geographically diverse, it is based on a small sample size and these findings may not be generalizable to all populations.
• The retrospective analysis used health insurance claims data and is dependent on reimbursement coding practices of physicians' offices, outpatient pharmacies, and hospitals; therefore, potential miscoding of medical claims and missing data are possible.
• The cost per persisting patient calculation uses the assumption that patients who persist on therapy are receiving a benefit and that the therapy is effective. This assumption is applied across all therapies included in the analysis. Future studies may use more comprehensive databases, such as electronic medical records, to capture clinical and patient reported outcomes measures of efficacy.
